115 related articles for article (PubMed ID: 37827342)
1. PROS1, a clinical prognostic biomarker and tumor suppressor, is associated with immune cell infiltration in breast cancer: A bioinformatics analysis combined with experimental verification.
He T; Sun X; Wu C; Yao L; Zhang Y; Liu S; Jiang Y; Li Y; Wang M; Xu Y
Cell Signal; 2023 Dec; 112():110918. PubMed ID: 37827342
[TBL] [Abstract][Full Text] [Related]
2. PROS1 shapes the immune-suppressive tumor microenvironment and predicts poor prognosis in glioma.
Wang J; Wu N; Feng X; Liang Y; Huang M; Li W; Hou L; Yin C
Front Immunol; 2022; 13():1052692. PubMed ID: 36685506
[TBL] [Abstract][Full Text] [Related]
3. LncRNA RP3-525N10.2-NFKB1-PROS1 triplet-mediated low PROS1 expression is an onco-immunological biomarker in low-grade gliomas: a pan-cancer analysis with experimental verification.
Zhou Y; Xiao D; Jiang X
J Transl Med; 2022 Jul; 20(1):335. PubMed ID: 35879775
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance and immune characteristics analysis of miR-221-3p and its key target genes related to epithelial-mesenchymal transition in breast cancer.
Fang Y; Zhang Q; Chen Z; Guo C; Wu J
Aging (Albany NY); 2024 Jan; 16(1):322-347. PubMed ID: 38189813
[TBL] [Abstract][Full Text] [Related]
5. Integrated analysis identifies TfR1 as a prognostic biomarker which correlates with immune infiltration in breast cancer.
Chen F; Fan Y; Hou J; Liu B; Zhang B; Shang Y; Chang Y; Cao P; Tan K
Aging (Albany NY); 2021 Sep; 13(17):21671-21699. PubMed ID: 34518441
[TBL] [Abstract][Full Text] [Related]
6. Transmembrane protein 92 performs a tumor-promoting function in breast carcinoma by contributing to the cell growth, invasion, migration and epithelial-mesenchymal transition.
Lin MZ; Teng LL; Sun XL; Zhang LP; Chen F; Yu LJ
Tissue Cell; 2020 Dec; 67():101415. PubMed ID: 32835947
[TBL] [Abstract][Full Text] [Related]
7. Identification of DRP1 as a prognostic factor correlated with immune infiltration in breast cancer.
Liu B; Fan Y; Song Z; Han B; Meng Y; Cao P; Tan K
Int Immunopharmacol; 2020 Dec; 89(Pt B):107078. PubMed ID: 33049497
[TBL] [Abstract][Full Text] [Related]
8. Identification of PIMREG as a novel prognostic signature in breast cancer via integrated bioinformatics analysis and experimental validation.
Zhao W; Chang Y; Wu Z; Jiang X; Li Y; Xie R; Fu D; Sun C; Gao J
PeerJ; 2023; 11():e15703. PubMed ID: 37483962
[TBL] [Abstract][Full Text] [Related]
9. Elevated expression of FREM1 in breast cancer indicates favorable prognosis and high-level immune infiltration status.
Li HN; Li XR; Lv ZT; Cai MM; Wang G; Yang ZF
Cancer Med; 2020 Dec; 9(24):9554-9570. PubMed ID: 33058542
[TBL] [Abstract][Full Text] [Related]
10. Investigating the role of FADS family members in breast cancer based on bioinformatic analysis and experimental validation.
Zhao T; Gao P; Li Y; Tian H; Ma D; Sun N; Chen C; Zhang Y; Qi X
Front Immunol; 2023; 14():1074242. PubMed ID: 37122728
[TBL] [Abstract][Full Text] [Related]
11. Anhydroicaritin Inhibits EMT in Breast Cancer by Enhancing GPX1 Expression: A Research Based on Sequencing Technologies and Bioinformatics Analysis.
Li F; Shi Y; Yang X; Luo Z; Zhang G; Yu K; Li F; Chen L; Zhao Y; Xie Y; Wu Y; Yang J; Zhou X; Liu S
Front Cell Dev Biol; 2021; 9():764481. PubMed ID: 35178395
[No Abstract] [Full Text] [Related]
12. Identification and comprehensive analysis of epithelial-mesenchymal transition related target genes of miR-222-3p in breast cancer.
Fang Y; Zhang Q; Chen C; Chen Z; Zheng R; She C; Zhang R; Wu J
Front Oncol; 2023; 13():1189635. PubMed ID: 37546414
[TBL] [Abstract][Full Text] [Related]
13. Identifying liver metastasis-related hub genes in breast cancer and characterizing
Chen M; Zheng W; Fang L
PeerJ; 2023; 11():e15311. PubMed ID: 37180578
[TBL] [Abstract][Full Text] [Related]
14. Overexpressed VDAC1 in breast cancer as a novel prognostic biomarker and correlates with immune infiltrates.
Fang Y; Liu J; Zhang Q; She C; Zheng R; Zhang R; Chen Z; Chen C; Wu J
World J Surg Oncol; 2022 Jun; 20(1):211. PubMed ID: 35729567
[TBL] [Abstract][Full Text] [Related]
15. RAB10 promotes breast cancer proliferation migration and invasion predicting a poor prognosis for breast cancer.
Zhuo J; Han J; Zhao Y; Hao R; Shen C; Li H; Dai L; Sheng A; Yao H; Yang X; Liu W
Sci Rep; 2023 Sep; 13(1):15252. PubMed ID: 37709911
[TBL] [Abstract][Full Text] [Related]
16. Hsa_circ_001569 is an unfavorable prognostic factor and promotes cell proliferation and metastasis by modulating PI3K-AKT pathway in breast cancer.
Xu JH; Wang Y; Xu D
Cancer Biomark; 2019; 25(2):193-201. PubMed ID: 31104012
[TBL] [Abstract][Full Text] [Related]
17. Let-7d and miR-185 Impede Epithelial-Mesenchymal Transition by Downregulating Rab25 in Breast Cancer.
Shahabi A; Naghili B; Ansarin K; Montazeri M; Dadashpour M; Zarghami N
Asian Pac J Cancer Prev; 2021 Jan; 22(1):305-313. PubMed ID: 33507713
[TBL] [Abstract][Full Text] [Related]
18. Identification of prognostic biomarkers for breast cancer brain metastases based on the bioinformatics analysis.
Wu Z; Wan J; Wang J; Meng X; Qian H
Biochem Biophys Rep; 2022 Mar; 29():101203. PubMed ID: 35059509
[TBL] [Abstract][Full Text] [Related]
19. Oncogenic signaling pathway-related long non-coding RNAs for predicting prognosis and immunotherapy response in breast cancer.
Li H; Liu H; Hao Q; Liu X; Yao Y; Cao M
Front Immunol; 2022; 13():891175. PubMed ID: 35990668
[TBL] [Abstract][Full Text] [Related]
20. miR-665 expression predicts poor survival and promotes tumor metastasis by targeting NR4A3 in breast cancer.
Zhao XG; Hu JY; Tang J; Yi W; Zhang MY; Deng R; Mai SJ; Weng NQ; Wang RQ; Liu J; Zhang HZ; He JH; Wang HY
Cell Death Dis; 2019 Jun; 10(7):479. PubMed ID: 31209222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
